In late-stage metastatic colorectal cancer, the goal shifts from achieving significant tumor shrinkage to stabilizing the disease. This recalibration of 'success' focuses on maintaining quality of life and managing symptoms for patients who have undergone multiple prior therapies.
Retesting for biomarkers with liquid biopsy in the third-line setting is crucial. It can uncover new, actionable mutations that have emerged during treatment or confirm the absence of resistance mutations, potentially allowing patients to benefit from re-challenging with a previously used targeted therapy.
In third-line mCRC, drug selection is heavily guided by a patient's accumulated toxicities. For instance, a patient with bone marrow issues from prior chemotherapy might receive a VEGF inhibitor instead of another chemotherapy agent, prioritizing tolerability and quality of life.
As more effective targeted therapies move into first- and second-line treatment, patients live longer. A paradoxical outcome is that more patients will survive long enough to become candidates for third-line therapy, potentially expanding this patient population rather than shrinking it.